Kynurenic acid ameliorates NLRP3 inflammasome activation by blocking calcium mobilization via GPR35

Tianyin Sun, Ruiqian Xie, Hongbin He, Qianqian Xie, Xueqin Zhao, Guijie Kang, Cheng Chen, Wenwei Yin, Jingjing Cong, Jing Li, Xuefu WangFrontiers in Immunology 2022 · DOI

TL;DR

This study reveals that kynurenic acid (KA), a tryptophan metabolite, acts as a novel inhibitor of the NLRP3 inflammasome, a key driver of inflammation and metabolic disorders. KA achieves this by blocking calcium mobilization via the GPR35 receptor, thereby preventing downstream mitochondrial damage and ultimately dampening inflammatory responses.

What Problem Does This Paper Address?

The NLRP3 inflammasome is a critical component of the innate immune system, but its dysregulation is implicated in a wide range of inflammatory and metabolic diseases, including sepsis, type 2 diabetes, and autoimmune disorders. While its activation is known to be tightly controlled, the precise mechanisms and potential endogenous regulators are still being uncovered. This paper investigates the role of kynurenic acid (KA), a naturally occurring metabolite, in modulating NLRP3 inflammasome activation, aiming to identify novel therapeutic avenues for these debilitating conditions.

Methods

The researchers employed a multi-pronged approach:

  • In vitro studies: They used primary bone marrow-derived macrophages (BMDMs) and THP-1 cells, a human monocyte cell line, to investigate KA's effects on NLRP3 inflammasome activation. Key techniques included:
  • Western blotting: To detect the cleavage of caspase-1 and maturation of IL-1β, as well as the expression of inflammasome components like NLRP3 and ASC.
  • ELISA: To quantify the release of inflammatory cytokines (IL-1β, IL-18, TNF-α) in cell culture supernatants.
  • LDH release assay: To assess pyroptosis, a programmed cell death mechanism triggered by inflammasome activation.
  • Immunofluorescence and confocal microscopy: To visualize mitochondrial damage and reactive oxygen species (ROS) production.
  • Cytosolic Ca²⁺ detection: Using fluorescent indicators to measure intracellular calcium levels.
  • Immunoprecipitation: To study the interaction between NLRP3 and ASC.
  • Intracellular potassium determination: To assess potassium efflux, another known upstream signal for NLRP3.
  • In vivo studies: Animal models were used to evaluate KA's therapeutic potential:
  • LPS-induced sepsis model: To assess KA's effect on systemic inflammation.
  • MSU-induced peritonitis model: To investigate KA's role in NLRP3-dependent peritoneal inflammation.
  • High-fat diet (HFD) model: To examine KA's impact on diet-induced metabolic disorders, including glucose tolerance and insulin resistance.
  • Genetic manipulation: The study utilized knockout mice (Nlrp3⁻/⁻ and Gpr35⁻/⁻) to elucidate the specific roles of NLRP3 and GPR35 in KA's mechanism of action.

Datasets

Not explicitly discussed as datasets in the traditional machine learning sense. The study relies on experimental data generated from cell cultures and animal models, as well as established reagents and cell lines.

Key Insights and Ideas

  • KA as a specific NLRP3 inhibitor: Unlike broad-spectrum anti-inflammatories, KA appears to selectively target the NLRP3 inflammasome, sparing other inflammasome pathways like NLRC4 and AIM2. This specificity is crucial for minimizing off-target effects.
  • Calcium mobilization as the key target: The most striking finding is that KA's primary mechanism involves blocking calcium influx. This is a novel insight, as previous research has focused more on potassium efflux or direct inflammasome component inhibition.
  • GPR35 as the mediator: The study strongly implicates G-protein coupled receptor 35 (GPR35) as the receptor through which KA exerts its inhibitory effects. This opens up GPR35 as a potential therapeutic target.
  • Translational relevance: The in vivo studies demonstrate that KA can effectively mitigate the severity of LPS-induced sepsis, MSU-induced peritonitis, and metabolic disorders associated with a high-fat diet, highlighting its therapeutic potential.

Key Results

  • KA suppressed caspase-1 activation and IL-1β production in both BMDMs and THP-1 cells in a dose-dependent manner.
  • KA inhibited the activation of NLRP3 inflammasomes triggered by various stimuli (nigericin, MSU, ATP) but not NLRC4 or AIM2 inflammasomes.
  • KA blocked ASC oligomerization and the NLRP3-ASC interaction, key steps in inflammasome assembly.
  • KA significantly reduced intracellular calcium mobilization induced by nigericin, while having no effect on potassium efflux.
  • KA attenuated mitochondrial damage and mtROS production, downstream consequences of calcium dysregulation.
  • In vivo, KA treatment improved survival in LPS-induced sepsis, reduced peritoneal inflammation in MSU-induced peritonitis, and ameliorated glucose intolerance and insulin resistance in HFD-fed mice.
  • The protective effects of KA were significantly diminished or abolished in GPR35 knockout mice, confirming GPR35's essential role.

Limitations and Future Work

  • Mechanism of KA-GPR35 interaction: While GPR35 is identified as the mediator, the precise downstream signaling pathways initiated by KA-GPR35 activation that lead to calcium channel inhibition require further elucidation.
  • Other potential receptors: KA is known to interact with other receptors like AHR. The study acknowledges that the role of these other receptors in KA's anti-NLRP3 activity needs further investigation.
  • Antioxidant properties: KA also possesses antioxidant properties, which might contribute to its effects on mitochondrial ROS. The study suggests that further investigation is needed to disentangle the contributions of calcium modulation versus direct antioxidant effects.
  • Long-term effects and side effects: While KA shows therapeutic promise, its long-term effects and potential side effects in humans require thorough investigation before clinical application.
  • Broader therapeutic potential: The study suggests that KA or other GPR35 agonists could be potential therapeutics for a range of NLRP3-triggered diseases, including neurodegenerative conditions and atherosclerosis, which warrants further exploration.

Summary updated

Abstract

The inflammasome has been linked to diverse inflammatory and metabolic diseases, and tight control of inflammasome activation is necessary to avoid excessive inflammation. Kynurenic acid (KA) is a tryptophan metabolite in the kynurenine pathway. However, the roles and mechanisms of the regulation of inflammasome activation by KA have not yet been fully elucidated. Here, we found that KA suppressed caspase-1 activation and IL-1β production in macrophages by specifically inhibiting canonical and noncanonical activation of the NLRP3 inflammasome. Mechanistically, KA reduced calcium mobilization through G-protein receptor 35 (GPR35), resulting in reduced mitochondrial damage and decreased mtROS production, thus blocking NLRP3 inflammasome assembly and activation. Importantly, KA prevented lipopolysaccharide-induced systemic inflammation, monosodium urate-induced peritoneal inflammation, and high-fat diet-induced metabolic disorder. Thus, KA ameliorated inflammation and metabolic disorders by blocking calcium mobilization-mediated NLRP3 inflammasome activation <i>via</i> GPR35. Our data reveal a novel mechanism for KA in the modulation of inflammasome activation and suggest that GPR35 might be a promising target for improving NLRP3 inflammasome-associated diseases by regulating calcium mobilization.
BibTeX
@inproceedings{sun2022kynurenic,
  author = {Tianyin Sun and Ruiqian Xie and Hongbin He and Qianqian Xie and Xueqin Zhao and Guijie Kang and Cheng Chen and Wenwei Yin and Jingjing Cong and Jing Li and Xuefu Wang},
  title = {{Kynurenic acid ameliorates NLRP3 inflammasome activation by blocking calcium mobilization via GPR35}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.1019365},
}

Loading related content...

Figure